中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
6期
13-14
,共2页
骨髓增生异常综合征%羟基喜树碱%预激治疗
骨髓增生異常綜閤徵%羥基喜樹堿%預激治療
골수증생이상종합정%간기희수감%예격치료
Myelodysplastic syndromes%Hydroxy camptothecin%Priming therapy
目的:观察含羟基喜树碱的预激方案治疗老年高危骨髓增生异常综合征(myelodysplastic syndrome,MDS)的临床疗效和不良反应.方法:联合羟基喜树碱、阿糖胞苷和粒细胞刺激因子组成CHG方案治疗21例老年高危MDS患者.结果:21例老年高危MDS患者完全缓解10例(47.6%),部分缓解4例(19.1%),血液学改善2例(9.5%),总有效率76.2%,不良反应轻.结论:含羟基喜树碱的预激方案是治疗老年高危MDS的有效方法,且不良反应轻,耐受性良好.
目的:觀察含羥基喜樹堿的預激方案治療老年高危骨髓增生異常綜閤徵(myelodysplastic syndrome,MDS)的臨床療效和不良反應.方法:聯閤羥基喜樹堿、阿糖胞苷和粒細胞刺激因子組成CHG方案治療21例老年高危MDS患者.結果:21例老年高危MDS患者完全緩解10例(47.6%),部分緩解4例(19.1%),血液學改善2例(9.5%),總有效率76.2%,不良反應輕.結論:含羥基喜樹堿的預激方案是治療老年高危MDS的有效方法,且不良反應輕,耐受性良好.
목적:관찰함간기희수감적예격방안치료노년고위골수증생이상종합정(myelodysplastic syndrome,MDS)적림상료효화불량반응.방법:연합간기희수감、아당포감화립세포자격인자조성CHG방안치료21례노년고위MDS환자.결과:21례노년고위MDS환자완전완해10례(47.6%),부분완해4례(19.1%),혈액학개선2례(9.5%),총유효솔76.2%,불량반응경.결론:함간기희수감적예격방안시치료노년고위MDS적유효방법,차불량반응경,내수성량호.
Objective:To observe the clinical efficacy and toxicity of CHG(Hydroxy camptothecin,cytarabine and granulocyte colony-stimulating factor)regimen in patients with hish-risk myelodysplastic syndromes(MDS). Method:A total of 21 elderly patients with high-risk MDS were treated with CHG regimen. Result:The results showed that 10 patients achieved complete remission(CR)(47.6%)and 4 patients achieved partial remission(PR)(19.1%)after one course of CHG regimen,and the total effective rate was 76.2%. Conclusion:It is concluded that the CHG regimen is safe and effective chemotherapy to elderly patients with high-risk MDS,and it was well tolerance.
